Dropping aspirin after a heart attack: a safer path or a risky gamble?

NCT ID NCT07736196

First seen Jul 30, 2026 · Last updated Jul 31, 2026 · Updated 1 time

Summary

This trial tests whether heart attack patients who have had complete artery-opening procedures can safely stop aspirin after 3-6 months and continue with only a P2Y12 inhibitor. The goal is to see if this approach reduces bleeding problems without increasing the risk of another heart attack, stroke, or blood clot. About 300 participants will be randomly assigned to either stop aspirin or stay on standard dual therapy, and researchers will track both bleeding events and cardiovascular outcomes over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
aspirin-free strategy with P2Y12 inhibitor monotherapy
What this could lead to
If successful, this could lead to a safer, simpler long-term antiplatelet regimen for heart attack patients, reducing bleeding complications.
What could go wrong
This is a single-center Phase 4 trial with 300 participants, so results may not apply broadly. Stopping aspirin could increase the risk of blood clots, heart attack, or stroke.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE CORONARY SYNDROME (ACS) UNDERGOING PERCUTANEOUS CORONARY INTERVENTION (PCI) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Assiut University Hospital

    Asyut, Asyut Governorate, 71515, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.